<DOC>
	<DOCNO>NCT02901431</DOCNO>
	<brief_summary>This Phase II multi-center , randomize , double-blind , 24-week , 3-arm , parallel group , placebo-controlled study investigate efficacy , safety , pharmacokinetics RO5285119 child adolescent age 5-17 year ASD high function ( intelligence quotient [ IQ ] great equal [ &gt; = ] 70 ) . Enrollment stagger , start first adolescent ( age 13 17 year ) child ( age 5 12 year ) . Initially , first cohort approximately 24 adolescent enrol together . Based pharmacokinetic evaluation , safety , tolerability first adolescent cohort determine final dos , enrollment adolescent resume enrollment first cohort approximately 24 child ( age 5 12 year ) commence . Based acceptable safety tolerability first child cohort determine final dos , enrollment child resume .</brief_summary>
	<brief_title>A Study Investigate Efficacy Safety RO5285119 Participants With Autism Spectrum Disorder ( ASD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<criteria>Fluent English Diagnostic Statistical Manual Mental Disorders , 5th Edition ( DSM5 ) criteria ASD International Statistical Classification Diseases Related Health Problems , 10th revision ( ICD10 ) criteria Autism diagnosis confirm Autism Diagnostic Observational Schedule ( ADOS2 ) criteria Social Responsiveness Scale , second edition ( SRS2 ) ( Tscore ) &gt; = 66 Clinical Global Impressions Severity ( CGIS ) &gt; = 4 ( moderately ill ) screen IQ &gt; = 70 assessed Wechsler Abbreviated Scale Intelligence Scale : Second Edition ( WASIII ) Wechsler Preschool Primary Scale Intelligence : Fourth Edition ( WPPSIIV ) intelligence test Language , hearing , vision compatible study measurement judge investigator Initiation major change psychosocial intervention ( include investigational ) within 4 week prior screen Unstable uncontrolled clinically significant psychiatric and/or neurological disorder may interfere safety efficacy endpoint Known personal family history cerebral aneurysm Risk suicidal behavior Seizure within past 6 month Medical history alcohol substance abuse/dependence Concurrent cardiovascular disease consider well control Investigator Clinically significant abnormality electrocardiogram screen Concomitant disease condition ( pulmonary , gastrointestinal , hepatic , renal , metabolic , immunological system , obesity could interfere conduct study Evidence current gastrointestinal bleeding , e.g. , active stomach ulcer disease History coagulopathies , bleed disorder , blood dyscrasia Positive serology hepatitis B ( HBV ) , hepatitis C ( HCV ) , human immunodeficiency virus ( HIV ) 1 , HIV 2 Confirmed clinically significant abnormality parameter hematology , clinical chemistry , coagulation , urinalysis Medical history malignancy consider cured Participation investigational drug study within 90 day 5 time halflife investigational molecule ( whichever longer ) prior randomization Loss blood 250 milliliter within three month prior screen Allowed medication stable since 4 week screen , allow medication treatment epilepsy stable since 3 month screen Use prohibit medication within 2 week prior screen visit 5 time halflife prior randomization ( whichever longer )</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>